Meeting the "Go" criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults